Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CAR-T Meeting 2024 | The need for alternative development pathways for CAR T-cell products

Andre Baruchel • 16 Feb 2024
CAR-T Meeting 2024
Acute Lymphoblastic Leukemia General Leukemia Rare Diseases CAR-T

In this video, André Baruchel, MD, PhD, Hospital Robert Debré AP-HP, Paris, France, discusses why alternative development pathways are needed for CAR T-cell products for the treatment of rare diseases in both the pediatric and adult setting. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Andre Baruchel

4:16
The challenges with CAR T-cell therapy for T-ALL and the progress made to overcome these challenges
Andre Baruchel • 16 Feb 2024
4:06
CAR-T therapy in ALL: exploring dual-targeting of CD19 & CD22 to overcome resistance
Andre Baruchel • 16 Feb 2024
7:41
Tisagenlecleucel in pediatric R/R B-cell ALL
Andre Baruchel • 28 Jun 2020
7:17
B-cell ALL with IGH-IL3 rearrangement and eosinophilia
Andre Baruchel • 16 Jul 2020

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
The content of VJHemOnc is intended for healthcare professionals